FDA Again Delays Approval Of Pfizer-BMS Anti-Clotting Drug
The U.S. Food and Drug Administration has again delayed its decision on whether to approve a drug designed to reduce the risk of blood clots and prevent stroke and systemic embolism,...To view the full article, register now.
Already a subscriber? Click here to view full article